Skip to main content
. 2026 Jan 20;18(1):8. doi: 10.21037/jtd-2025-1861

Figure 2.

Figure 2

Comparative Kaplan-Meier analysis of progression-free survival in NSCLC patients between the AM group and PM groups. AP, pemetrexed plus platinum; CI, confidence interval; HR, hazard ratio; mPFS, median progression-free survival; NSCLC, non-small cell lung cancer.